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abstract
 
Flecainide (pKa 9.3, 99% charged at pH 7.4) and lidocaine (pKa 7.6–8.0, 
 
 
 
50% neutral at pH 7.4)
have similar structures but markedly different effects on Na
 
 
 
 channel activity. Both drugs cause well-characterized
use-dependent block (UDB) of Na
 
 
 
 channels due to stabilization of the inactivated state, but ﬂecainide requires
that channels ﬁrst open before block develops, whereas lidocaine is believed to bind directly to the inactivated
state. To test whether the charge on ﬂecainide might determine its state speciﬁcity of Na
 
 
 
 channel blockade, we
developed two ﬂecainide analogues, NU-FL (pKa 6.4), that is 90% neutral at pH 7.4, and a quaternary ﬂecainide
analogue, QX-FL, that is fully charged at physiological pH. We examined the effects of ﬂecainide, NU-FL, QX-FL,
and lidocaine on human cardiac Na
 
 
 
 channels expressed in human embryonic kidney (HEK) 293 cells. At physio-
logical pH, NU-FL, like lidocaine but not ﬂecainide, interacts preferentially with inactivated channels without pre-
requisite channel opening, and causes minimal UDB. We ﬁnd that UDB develops predominantly by the charged
form of ﬂecainide as evidenced by investigation of QX-FL at physiological pH and NU-FL investigated over a more
acidic pH range where its charged fraction is increased. QX-FL is a potent blocker of channels when applied from
inside the cell, but acts very weakly with external application. UDB by QX-FL, like ﬂecainide, develops only after
channels open. Once blocked, channels recover very slowly from QX-FL block, apparently without requisite chan-
nel opening. Our data strongly suggest that it is the difference in degree of ionization (pKa) between lidocaine
and ﬂecainide, rather than gross structural features, that determines distinction in block of cardiac Na
 
 
 
 channels.
The data also suggest that the two drugs share a common receptor but, consistent with the modulated receptor hy-
pothesis, reach this receptor by distinct routes dictated by the degree of ionization of the drug molecules.
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INTRODUCTION
 
Investigation of ion channel defects associated with the
long QT syndrome (LQTS)* has provided new insights
into fundamental mechanisms through which ion
channel activity and its modulation by drugs control
the duration of the cardiac ventricular action potential
and consequently the QT interval of the electrocardio-
gram (EKG). In particular, the unanticipated discovery
of mutations in SCN5A, the gene coding for the 
 
 
 
 sub-
unit of the heart voltage–gated Na
 
 
 
 channel, associated
with LQTS variant 3 (LQT-3) and the use of Na
 
 
 
 chan-
nel blockers to control QT prolongation in LQT-3 mu-
tation carriers has renewed interest into the fundamen-
tal mechanism of actions of drugs that block Na
 
 
 
 chan-
nels (An et al., 1996; Dumaine and Kirsch, 1998;
Kambouris et al., 2000; Viswanathan et al., 2001).
Flecainide, the prototypical Class 1c antiarrhythmic
agent, is of particular interest because it has been
shown to be more effective than lidocaine, a prototypi-
cal Class 1b agent, in the management of QT prolonga-
tion in some LQT-3 mutation carriers (Brugada et al.,
1999; Benhorin et al., 2000). Additionally, ﬂecainide
is used in diagnostic tests to identify patients at risk
for the Brugada syndrome, an inherited form of idio-
pathic ventricular ﬁbrillation that too is associated with
SCN5A mutation (Brugada et al., 1999). Clearly, under-
standing fundamental differences between the mecha-
nisms of action of ﬂecainide and lidocaine has signiﬁ-
cance, not only from the point of view of the funda-
mental molecular pharmacology of the cardiac Na
 
 
 
channel, but also for its importance in detecting and
treating these inherited arrhythmias.
Flecainide and lidocaine have similar chemical struc-
tures but markedly different effects on sodium channel
activity. Both drugs promote tonic and use channel
state–dependent block (block that increases with chan-
nel activity) of Na
 
 
 
 channels. The afﬁnity of lidocaine
is higher for inactivated compared with resting chan-
nels, and hence the stabilization of inactivated lido-
caine-bound channels has been shown to underlie its
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state-dependent Na
 
 
 
 channel block (Hille, 1977a). In
contrast with lidocaine, ﬂecainide requires channels to
open before it causes use-dependent block (UDB) and
consequently has been associated with block of open
channels (Anno and Hondeghem, 1990; Ragsdale et
al., 1996; Liu et al., 2002). However, investigation of dis-
ease-associated mutant cardiac Na
 
 
 
 channels recently
has provided evidence that although necessary, chan-
nel openings are not sufﬁcient to explain ﬂecainide
UDB. Instead, like lidocaine, ﬂecainide block may be
determined by preferential interaction with inactivated
channels (Liu et al., 2002). Further, the results of that
study suggested that differential access to a common re-
ceptor might account for differences between these
two drugs.
Investigation into differential access to a common re-
ceptor has been hampered by differences in the physi-
cal chemical properties of the two drugs. Lidocaine has
a pKa between 7.8–8.6 and thus may be up to 50% neu-
tral at physiological pH. In contrast, ﬂecainide has a
pKa of 
 
 
 
9.3, resulting in 
 
 
 
99% of the drug in ionized
and 
 
 
 
1% in neutral forms at pH 7.4 (Hille, 1977a; Stri-
chartz et al., 1990). Thus, the charge on ﬂecainide is
likely to restrict access of the drug to a receptor site,
confer the dependence of use-dependent block on
channel openings, and account for most of the differ-
ences between it and lidocaine (Strichartz, 1973; Hille,
1977a; Chernoff and Strichartz, 1990). However, a di-
rect test of this possibility has not been possible because
of the marked differences in distribution between neu-
tral and charged forms of each compound.
Here we employed two custom-synthesized ﬂecainide
analogues, NU-FL and QX-FL, to investigate the molec-
ular determinants of ﬂecainide activity. NU-FL has
nearly identical hyrophobicity and very similar three-
dimensional structure compared with ﬂecainide, but has
a very different pK
 
a
 
. As measured by titration, NU-FL
has an approximate pK
 
a
 
 value of 6.4. Consequently, it
should be nearly 90% neutral at physiological pH, thus
more closely resembling the ionization proﬁle of li-
docaine. QX-FL shares a very similar three-dimensional
structure with the parent compound ﬂecainide, but is
fully charged at physiological pH, and thus is well
suited to discriminate between hydrophilic and hydro-
phobic access to its receptor. We compared the effects
of ﬂecainide, NU-FL, QX-FL, and lidocaine on human
heart (hH1) sodium channels expressed in human em-
bryonic kidney (HEK) 293 cells to better understand
the speciﬁc mechanism of block by ﬂecainide. Our re-
sults indicate that like lidocaine, the tertiary ﬂecainide
analogue (NU-FL) interacts preferentially with inacti-
vated channels without prerequisite channel openings,
while ﬂecainide (and QX-FL) is ineffective in blocking
channels that inactivate without ﬁrst opening. Ionized
ﬂecainide underlies UDB. Our results show marked
 
UDB of channels by internally, but not externally, ap-
plied QX-FL, with voltage and time-dependent charac-
teristics consistent with intracellular access to a com-
mon receptor for local anesthetic molecules. QX-FL
block requires the open conformation of the channel,
suggesting that channel openings unmask a preferred
intracellular access route allowing QX-FL to bind to the
LA receptor site in the inner mouth of the channel
pore. Further, because the slow recovery of channels
from QX-FL block was impeded by outer pore block by
tetrodotoxin, our data also suggest that drug can dif-
fuse away from channels via the outer pore even in the
absence transitions into the open state. Our data
strongly suggest that it is the difference in degree of
ionization (pKa) between lidocaine and ﬂecainide,
rather than differences in their gross structural fea-
tures, that determines distinction in block of cardiac
Na
 
 
 
 channels. The data also suggest that the two drugs
share a common receptor, but, as outlined in the mod-
ulated receptor hypothesis, reach this receptor by dis-
tinct routes.
 
MATERIALS AND METHODS
 
Synthesis of NU-FL (2,5-bis(2,2,2-Triﬂuoroethoxy)N-(2 
Ethylmorpholino)Benzamide)
 
Crude 2,5-bis(2,2,2-triﬂuoroethoxy)benzoyl chloride (75 mg,
0.22 mmol), prepared by modiﬁcation of previously published
methods (Banitt et al., 1975), is dissolved in 10 ml of dichlo-
romethane under inert conditions. The solution is cooled to 0
 
 
 
C,
treated with N-aminoethylmorpholine (39 
 
 
 
l, 0.29 mmol), and
double distilled Hünigs base (43 
 
 
 
l, 0.24 mmol). After reacting
for 24 h at ambient temperature, the solution is concentrated,
dissolved into 15 ml of 5:1 ethyl acetate:diethyl ether, and washed
with equal portions of 10% sodium hydroxide, saturated sodium
chloride, and distilled water. The organic layers are separated,
dried over sodium sulfate, and concentrated to an oil. The oil is
recrystallized from ethyl acetate:hexanes at 
 
 
 
78
 
 
 
C in a CO
 
2
 
/ace-
tone bath. The precipitate is collected by suction ﬁltration,
washed with cold hexanes, and dried under vacuum to yield the
product (89 mg, 93%) as a white solid. TLC (EtOAc:Hex 1:5)
shows one major UV active spot with R
 
f
 
 
 
 
 
0.75. 
 
1
 
H NMR (d
 
6
 
-
DMSO, 300 MHz): 
 
 
 
 8.0 (br s., 1H), 7.3 (s, 1H), 7.2 (m, 2H), 4.7–
4.9 (m, 2H) 3.5–3.6 (m, 4H), 3.3–3.4 (m, 2H), 2.3–2.5 (m, 6H)
Mass: (APCI
 
 
 
) 430.6 (M
 
 
 
1). The material can subsequently be
converted to the hydrogen chloride salt by treatment of an ether
solution with 1.1 molar equivalents of concentrated HCl, ﬁltra-
tion, and lyophilization of an aqueous solution of the salt.
 
Synthesis of QX-FL (N,N-Dimethyl Flecainide)
 
Flecainide hydrogen chloride salt (55 mg, 0.122 mmol), potas-
sium carbonate (37 mg, 0.270 mmol), and iodomethane (0.54
mmol) are dissolved into a round bottom ﬂask charged with 5 ml
of absolute ethanol. The suspension is stirred at 25
 
 
 
C until TLC
(20:1:1 CH
 
2
 
Cl
 
2
 
:MeOH:NH
 
3
 
) demonstrates only baseline mate-
rial, after which time the ethanol is removed under reduced pres-
sure, the residue is solidiﬁed by trituration with anhydrous ether,
and cold distilled water (5 ml) added. The remaining solid is ﬁl-
tered and washed with 5 ml of cold water. The residue is col-
lected, dissolved into 30 mL of distilled water and lyophilized toT
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yield the product as the iodide salt (30 mg, 29%). 
 
1
 
H NMR (d
 
6
 
-
DMSO, 300 MHz): 
 
 
 
 8.5 (t, 1H, NH), 7.1–7.3 (m, 3H), 4.7–4.8
(m, 4H), 3.9 (d, 1H), 3.2 (s, 3H), 3.0 (s, 3H), 1.2–2.1 (m, 6H).
Mass (FAB
 
 
 
): Expected: 568 Found: 443 (M-I).
 
Mutagenesis and Expression of Recombinant Na
 
 
 
 channels
 
Mutations of 
 
SCN5A
 
 were engineered into WT cDNA cloned in
pcDNA3.1 (Invitrogen) by overlap extension using mutation-spe-
ciﬁc primers and Quick Change site-directed mutagenesis kit
(Stratagene) as described previously (Abriel et al., 2001). The
presence of the mutation was conﬁrmed by sequence analysis.
WT and mutant Na
 
 
 
 channels were expressed in HEK293 cells as
described previously (Abriel et al., 2001). Transient transfections
were performed with equal amounts of Na
 
 
 
 channel 
 
 
 
 subunit
and with h
 
 
 
1
 
, subcloned individually into the pcDNA3.1 (Invitro-
gen) vector (total cDNA 2.5 
 
 
 
g) using a previously described li-
pofection procedure (Abriel et al., 2001). Expression of channels
was studied using patch clamp procedures 48 h after transfec-
tion.
 
Electrophysiology
 
Membrane currents were measured using whole cell patch-clamp
procedures, with Axopatch 200B ampliﬁers (Axon Instruments,
Inc.). Recordings were made at room temperature (22
 
 
 
C) or
32
 
 
 
C where indicated. The internal pipette solution contained
(in mmol/L): aspartic acid 50, CsCl 60, Na
 
2
 
-ATP 5, EGTA 11,
HEPES 10, CaCl
 
2
 
 1, and MgCl
 
2
 
 1, with pH 7.4 adjusted with
CsOH (Abriel et al., 2001). External solutions consisted of
(mmol/L) NaCl 130, CaCl
 
2
 
 2, CsCl 5, MgCl
 
2
 
 1.2, HEPES 10, and
glucose 5, with pH 7.4 adjusted with CsOH. The external solu-
tion for cell-attached recordings was: (mM) 140 KCl, 5 HEPES, 1
MgCl
 
2
 
, and pH adjusted to 7.4. For cell-attached recordings, pi-
pettes were coated with Sylgard (Dow Chemical Co.) to decrease
noise and capacitance of the glass, and electrode resistance was
typically 1–2 M
 
 
 
 when ﬁlled with internal solution containing
110 mM NaCl, 10 mM HEPES (pH adjusted to 7.4).
In experiments designed to measure the voltage dependence
of activation, external Na
 
 
 
 was reduced to 30 mM using n-methyl-
glucamine as an Na
 
 
 
 substitute. Activation curves were deter-
mined by normalization of peak current versus voltage to driving
force determined as the difference between test voltage and mea-
sured channel reversal potential in low external Na
 
 
 
. Steady-state
inactivation was measured with 5-s conditioning pulses followed
by a test pulse (
 
 
 
10 mV), with an interpulse interval of 10 s.
Steady-state UDB was reached in response to trains of variable
numbers of pulses (100–600
 
 
 
, 
 
 
 
10 mV), at frequencies indi-
cated in the ﬁgure legends. This was sufﬁciently long to induce
steady-state UDB for each construct. UDB was measured as the
ratio of peak current at 
 
 
 
10 mV after and before application of a
conditioning train and is reported as the percentage block of
peak current.
Pclamp 8.0 (Axon Instruments, Inc.), Excel (Microsoft), and
Origin (Microcal Software) were used for data acquisition and
analysis. Data are presented as mean values 
 
 
 
 SEM. P 
 
  
 
0.05 was
considered statistically signiﬁcant (using Student’s 
 
t
 
 test).
 
RESULTS
 
Use-dependent Block by Flecainide and Its Tertiary Analogue
 
The chemical synthesis of both tertiary ﬂecainide (NU-
FL) and quaternary ﬂecainide (QX-FL) was generally
based on procedures reported in the literature for the
synthesis of related ﬂecainide analogues (Banitt et al.,
Figure 1. NU-Fl and QX-FL
are novel analogues of
ﬂecainide. (A) Structural
comparison of ﬂecainide and
its novel analogues NU-FL
(center) and QX-FL (right).
(B) Plot of estimated concen-
trations of charged drugs as
function of pH. The pKa val-
ues of each compound are
9.3 for ﬂecainide ( ), 6.4 for
NU-FL ( ), 7.8 for lidocaine
( ). At relevant physiologi-
cal pH values ﬂecainide is
 99% charged, QX-FL ( )
is fully ionized, lidocaine is
 50:50, and NU-FL is  90%
neutral.T
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1975). To the best of our knowledge these are novel
ﬂecainide analogues. Fig. 1 compares the structures of
NU-FL, QX-FL, and ﬂecainide and illustrates the rela-
tive distributions of neutral and charged drug forms as
a function of solution pH. The experimentally deter-
mined pK
 
a
 
 of NU-FL was 
 
 
 
6.4. Thus, at physiologic pH
(7.4), 90% of the drug is neutral. Altering the pH of
drug-containing solutions alters the ionized fraction of
NU-FL. At pH 8.4, the drug is 99% neutral, whereas at
pH 5.4 it is 90% charged. In contrast, because the pKa
of ﬂecainide is 9.3, it remains 
 
 
 
98% charged over this
pH range, and QX-FL is fully ionized over this pH
range.
We initially focused on the actions of NU-FL to deter-
mine whether neutral or charged drug forms caused
UDB. Fig. 2, A and B, shows that at similar concentra-
tions and using similar voltage protocols, much less
UDB develops in the presence of NU-FL than ﬂecain-
ide. Apparently at the pulse frequency of these experi-
ments (10 Hz) the interpulse interval (75 ms) during
the pulse train is sufﬁciently long to allow for unblock
of most NU-FL bound channels. Increasing the NU-FL
concentration to 100 
 
 
 
M such that the estimated con-
centration of ionized NU-FL is 10 
 
 
 
M results in UDB
comparable to that caused by 10 
 
 
 
M ﬂecainide. Be-
cause only 10% of NU-FL is charged at physiological
pH, this result suggests that the block that builds with
repetitive depolarization to voltages that open channels
(UDB) develops predominantly by the charged forms
of both ﬂecainide and NU-FL. This might be the case if
both charged and neutral drug forms gain access to a
common receptor during the brief depolarizing pulses,
but that, upon return to 
 
 
 
100 mV, channels can re-
cover quickly from neutral drug block, but not from
block by ionized drugs. If this were the case, then in-
creasing the ratio of charged to neutral drug mole-
cules, while keeping total drug concentration constant,
should increase the development of UDB with this volt-
age protocol. The data in Fig. 2 C indicate that this is
indeed the case. As summarized in the ﬁgure, as extra-
cellular pH is lowered and the fraction of ionized NU-
FL increased, UDB also increases despite the fact that
total NU-FL concentration is constant.
As proposed above, the difference in UDB that devel-
ops for NU-FL and ﬂecainide at pH 7.4 may be due in
large part to the difference between the kinetics of the
recovery from block by neutral and charged drug
forms. Recovery from drug block by both NU-FL and
Figure 2. UDB of WT Na  channels by ﬂecainide and NU-FL. Currents were evoked by imposing conditioning trains of 100–600 pulses
( 10 mV, 25 ms) from a holding potential of  100 mV at a frequency of 10 Hz. Pulses were applied until steady-state UDB was achieved.
This pulse protocol allows for a 75-ms interpulse interval at the holding potential between conditioning pulses. (A) Examples of current
traces recorded at 10 Hz before and after steady-state UDB (arrows) by ﬂecainide (10  M), NU-FL (10  M), and NU-FL (100  M). Cur-
rents are superimposed records of ﬁrst and last ( 300th) pulse of a conditioning train. (B) Bar graphs summarize steady-state UDB by
ﬂecainide and NU-FL, plotted as the fraction of current blocked in response to pulse trains (n   4–6 cells per condition). (C) Percent
UDB plotted vs. pH in the presence of 100  M NU-FL (n   4–6 cells per condition).T
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ﬂecainide at physiological pH is illustrated in Fig. 3.
Exponential ﬁts to the recovery kinetic data revealed
the following recovery time constants (
 
 
 
1
 
(fast) and 
 
 
 
2
 
(slow)): 55 ms and 508 ms for NU-FL, 103 ms and 2,530
ms for ﬂecainide. Recovery is signiﬁcantly faster for
NU-FL than for ﬂecainide. Because NU-FL is 90% neu-
tral at pH 7.4, the most likely difference in the recovery
kinetics is due to rapid unblock of neutral drug-bound
channels and very slow unblock of charged drug-bound
channels.
Recovery from NU-FL block in solutions buffered to
pH 5.5, when the ratio of neutral to charged forms of
NU-FL are reversed, is greatly slowed, consistent with
this hypothesis. Finally, we also illustrate recovery from
channel block by the permanently charged analogue
QX-FL in panel A, which is remarkably similar to recov-
ery from ﬂecainide block. At pH 7.4 there are both
neutral and ionized forms of ﬂecainide and NU-FL,
and thus the time course of recovery from block for
these drugs are complex. As proposed by Hille and col-
leagues in the analysis of the pH dependence of use-
dependent block of Na
 
 
 
 channels in muscle and nerve
(Hille, 1977a,b; Schwarz et al., 1977), during interpulse
intervals bound charged drug is trapped within the
channel until the drug molecule is deprotonated. Neu-
tral drug, which is less restricted (Hille, 1977a), can dis-
sociate from the channel at these voltages between con-
ditioning pulses. At pH 5.5 (Fig. 3 B), when 
 
 
 
90% of
NU-FL molecules are ionized, the recovery from inacti-
vation closely resembles that of ﬂecainide at pH 7.4
(Fig. 3 A), suggesting similar kinetics when both drugs
are ionized. At physiological pH, the fact that the recov-
ery from block is faster for NU-FL than for ﬂecainide
may simply be due to the greater contribution (90%) of
drug block by the neutral NU-FL component com-
pared, while ﬂecainide remains 
 
 
 
99% charged. On the
other hand, according the scheme described above, it
is possible that deprotonation of NU-FL, which can oc-
cur when channels are closed and at rest (Schwarz et
al., 1977), may occur faster than deprotonation of
ﬂecainde, and that the differences in recovery kinetics
occur not only because of the greater fraction of neu-
tral NU-FL molecules at this pH, but also because the
ionized bound drug deprotonates faster than ionized
bound ﬂecainde leave the vicinity of the receptor via a
hydrophobic pathway. Our data thus indicate that UDB
develops predominantly as a function of differences
between the recovery kinetics of ionized and neutral
Figure 3. Recovery from UDB by ﬂecainide, QX-FL, and NU-FL. UDB was induced by trains of 100 pulses ( 10 mV, 25 ms, 25 Hz) from
a  100 mV holding potential. Test pulses were then imposed after variable recovery intervals at  100 mV. Currents were normalized to
steady-state current levels during slow pacing (once every 30 s) and plotted against recovery interval in the absence and presence of
ﬂecainide (10  M) and NU-FL (100  M), and NU-FL (pH 5.5, 100  M). Recovery from UDB by QX-FL, ﬂecainide, and NU-FL. UDB was
induced by trains of 100 pulses ( 10 mV, 25 ms, 25 Hz) from a  100 mV holding potential. Test pulses were then imposed after variable
recovery intervals at  100 mV. Currents were normalized to steady-state current levels during slow pacing (once every 30 s) and plotted
against recovery interval in the absence and presence of test drugs. (A) Drugs studied at pH 7.4 were ﬂecainide (10  M), NU-FL (100
 M), and QX-FL (internal, 200  M). (B) Similar protocols were performed in solutions buffered to pH 5.5 in the absence and presence of
NU-FL (100  M). The averaged data were ﬁtted with a two exponential function: y(t)   y0   A1   exp-t/ 1   A2   exp-t/ 2), where t is the
recovery time,  1 and  2 are the recovery time constant, A1 and A2 are fractional amplitudes of each component, and y0 is the estimated
steady-state fraction of recovered current. n   3–5 cells per condition.T
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drug molecules. This proﬁle closely resembles that of
lidocaine, raising the question as to whether or not the
molecular pharmacology of lidocaine and NU-FL, in-
cluding channel state dependence of block, share simi-
lar proﬁles.
Channel Openings Are Required for Block by Charged, but Not 
Neutral, Flecainide
UDB by ﬂecainide requires that channels ﬁrst open be-
fore block develops (Ragsdale et al., 1996; Liu et al.,
2002). If this dependence on channel openings is due
to restricted receptor access caused by the predomi-
nantly ionized form of the drug, this requirement
should be reduced or eliminated for NU-FL, a greater
fraction of which is neutral at pH 7.4. Fig. 4 shows that
this is in fact the case. Shown in the ﬁgure are currents
measured at a ﬁxed voltage, but after trains of condi-
tioning pulses have been applied to a series of voltages.
Reduction in current measured during the test pulse is
a reﬂection of block that develops in a use-dependent
manner during the conditioning pulse trains (Ragsdale
et al., 1994, 1996). As has been shown previously by us
(Liu et al., 2002), ﬂecainide block develops during the
conditioning train, but only after pulses are applied to
voltages more positive than  45 mV, a voltage near the
activation threshold for Na  channels. A similar proﬁle
emerged for the voltage dependence of channel block
by QX-FL (ﬁlled circles), indicating that channel open-
ings are a common prerequisite for QX-FL and ﬂecain-
ide Na  channel block. This suggests that the open
state conformation is necessary for the ionized form of
the drug to reach its receptor. In contrast with the ex-
periments illustrated in Fig. 2, the pulse frequency (25
Hz) in these experiments, which allows only a 15-ms in-
terpulse interval between conditioning pulses, was sufﬁ-
ciently fast to promote channel block by NU-FL during
the conditioning trains. UDB by NU-FL is apparent af-
ter conditioning voltages as negative as  80 mV, volt-
ages consistent with a decrease in channel availability
that is not dependent on channel openings.
The data of Fig. 4 suggest a preferential interaction
of neutral ﬂecainide (NU-FL) with inactivated channels
that does not require channel openings to develop, a
suggestion that predicts drug-dependent alteration of
the voltage dependence of channel availability. Thus,
we compared the effects of NU-FL with lidocaine and
ﬂecainide on the voltage dependence of channel avail-
ability in the absence of trains of conditioning pulses to
ﬁrst open channels. Under these conditions, as previ-
ously shown (Liu et al., 2002), ﬂecainide has little effect
on channel availability (Fig. 5 A). In contrast, lidocaine
(Fig. 5 B) causes a well-documented negative shift in
channel availability under the same voltage conditions.
The tertiary ﬂecainide analogue NU-FL (100  M,  10
Figure 4. Voltage depen-
dence of UDB of Na  chan-
nels by ﬂecainide, QX-FL,
and NU-FL. Currents were re-
corded before (control) and
after (test) application of con-
ditioning pulses (100 pulses,
25 Hz) of varying amplitude
in the presence of ﬂecainide
(10   M), QX-FL (100  M,
internal), and NU-FL (100
 M). The pulse protocol al-
lows for a 15-ms interpulse in-
terval at the holding poten-
tial during the conditioning
trains. Test pulses were pre-
ceded by a 100 ms pulse-free
interval at the holding poten-
tial ( 100 mV) to allow drug-
free channels to recover from
inactivation. (A) Current
traces from experiments with
ﬂecainide (right), QX-FL
(middle), and NU-FL (left)
elicited by a control depolar-
ization before and by test de-
polarization after condition-
ing trains to  80 mV 0 mV.
(B) Normalized block is plotted vs. conditioning pulse amplitude for NU-FL ( ), QX-FL ( ), and ﬂecainide ( ). Normalized block was
determined as the fraction of test pulse current (normalized to control current) reduced by the conditioning train (n   3–4 cells per mea-
surement).T
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 M charged) also shifts channel availability without
conditioning pulses, similar to lidocaine but in contrast
to ﬂecainide (Fig. 5 C). Thus, although nearly identical
to ﬂecainide in structure, NU-FL interacts with the in-
activated state without mandatory channel openings
similar to lidocaine, a drug with a signiﬁcant neutral
component at physiological pH. When similar experi-
ments are carried at pH 8.0, solutions for which a
greater fraction of NU-FL is neutral, a lower total NU-
FL concentration causes a similar shift in channel avail-
ability, providing additional evidence that it is the neu-
tral form of NU-FL that interacts with the inactivated
channel in these experiments (unpublished data).
NU-FL: High-afﬁnity Block of Inactivated Channels
We next determined whether NU-FL, like lidocaine,
has a higher afﬁnity for the inactivated rather than the
resting state and illustrate the results of these experi-
ments in Fig. 6. A voltage protocol was used to inacti-
vate (5-s pulse to  40 mV), but not open, most chan-
nels in the absence and presence of drug. A test pulse
to  10 mV, preceded by a 3-ms return to the negative
( 100 mV) holding potential to allow drug-free, but
not drug-bound, channels to recover from inactivation
was applied to assay available channels. The concentra-
tion dependence of the block of channels during this
test pulse with and without conditioning pulses pro-
vides an estimate of rested state (no conditioning
pulse) and inactivated state (with conditioning pulse)
channel block (Weiser et al., 1999). Concentration-
response curves obtained using this protocol showed
that the neutral analogue inhibited Na  channels after
conditioning pulses (inactivated state block) with an
EC50 value of 5.32   0.51  M, which is comparable to
that obtained for lidocaine (3.46   0.33  M) using the
same voltage protocol. Rested state block (no prepulse)
revealed an EC50 values of 794   39  M (NU-FL) and
895   55  M (lidocaine). Thus, NU-FL and lidocaine
displayed 150- and 250-fold higher afﬁnities for inacti-
Figure 5. Effects of ﬂecainide, NU-FL, and lidocaine on steady-state inactivation of WT Na  channels. Steady-state inactivation was mea-
sured with 5-s conditioning pulses followed by a test pulse ( 10 mV) with an interpulse of 10 s. Graphs show normalized current plotted
against conditioning pulse voltage. Smooth lines are according to 1/{1   exp[(Vc   V1/2)/k]}, where Vc is conditioning potential, V1/2 is
voltage for which half the channel are not available, and k is a slope factor. The drug-induced shift in channel availability ( V1/2) was deter-
mined from V1/2,drug   V1/2,control using V1/2 values obtained from ﬁts of the data.  V1/2 is  2.3   0.29 mV with 10  M ﬂecainide,  9.17  
1.04 mV with 100  M NU-FL,  10.28   0.61 mV with 100  M lidocaine (n   4–6 cells per condition).T
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vated compared with resting Na  channels. The data
suggest that a simple change in the hydrophobicity
(charge) of ﬂecainide from predominantly charged to
neutral results in a dramatic change ﬂecainide action:
block of inactivated channels without prerequisite
channel openings.
Flecainide Blocks Na  Channels via an Intracellular Pathway
Delineating drug access to its receptor is critical in un-
derstanding the structural basis of drug action. Fig. 7
shows that, in the whole-cell recording mode, external,
but not internal, application of ﬂecainide promotes
UDB of heart Na  channels. The ﬁgure shows records
and summary data of experiments in which trains of re-
petitive depolarizing pulses (10 Hz,  10 mV, 25 ms)
were applied to cells expressing cardiac Na  channels
in the presence of ﬂecainide (10  M). As shown in the
ﬁgure, including ﬂecainide in the recording pipette
(cells were dialyzed for 3 min before applying UDB
protocols) has almost no effect on Na  channel cur-
rent, whereas bath application of the same ﬂecainide
concentration causes marked UDB of the channels
(67.3   3.5% vs. 8.4   1.5% for internal application,
P   0.01, n   4–5 cells). Increasing the ﬂecainide (10
 M) dialysis time from 3 to 10 min increased the
amount of UDB measured to 15   1.0%, still less than
four times the amount of UDB induced by external
ﬂecainide (10  M) application. These data are consis-
tent with extracellular, but not intracellular, access to a
receptor for ﬂecainide. However, although predomi-
nantly charged, a small fraction of ﬂecainide molecules
( 1%) is neutral at physiological pH, and thus another
interpretation of these results is possible. It is possible
that neutral ﬂecainide diffuses across the cell mem-
brane, reaches equilibrium within the cell and again
partitions into charged ( 99%) and neutral ( 1%)
forms such that drug block occurs via intracellular
ﬂecainide. Pipette application of the drug would be ex-
pected to have little effect as drug applied essentially as
a point source in the cell, diffuses out of the cell via its
neutral component and would be quickly diluted and
washed away in the extracellular bath.
To determine whether or not this may be the case, we
repeated the experiments of Fig. 7, but replaced
ﬂecainide by QX-FL (10  M) to determine whether re-
moval of the small fraction of neutral ﬂecainide affects
the apparent sidedness of drug action on cardiac Na 
channels. UDB was measured under conditions of both
external and internal drug application and the sided-
ness of drug block was opposite to that for ﬂecainide.
As shown in Fig. 8, UDB by externally applied QX-FL
was very weak; however, internal application of QX-FL
(3 min dialysis time before assaying for UDB) resulted
in marked UDB. Because QX-FL cannot diffuse across
the cell membrane, these data clearly indicate that an
intracellular pathway dominates for ionized ﬂecainide
block of heart Na  channels. These results, very similar
to those obtained in similar experiments with the
Figure 6. Afﬁnity of resting
and inactivated states of WT
Na  channels for NU-FL and
lidocaine. The block of rest-
ing Na  channels was investi-
gated by depolarizing to  10
mV from a holding potential
of  100 mV. The block of in-
activated Na  channels was
measured using 5-s depolariz-
ing prepulse to  40 mV to in-
activated most channels and
the membrane potential then
was returned to the holding
potential for 3 ms to allow
drug-free channels to recover
from inactivation. A test pulse
to  10 mV then was applied.
The block of peak test pulse
current is plotted as a func-
tion of drug concentration.
The smooth curves are the
best ﬁts of the Hill equation
1/((1     ([drug]/EC50)n) to
the data, these gave estimates
of EC50 for drug binding to
resting and inactivated chan-
nels. For the resting channels, EC50 are 794   39.3  M for NU-FL ( ) and 895   55.4  M for lidocaine ( ). For the inactivated channels,
EC50 are 5.32   0.51  M for NU-FL ( ) and 3.46   0.33  M for lidocaine ( ) (n   3–5 cells per condition).T
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lidocaine analogue QX-314 (Fig. 8 C), show that the
small fraction of neutral ﬂecainide molecules compli-
cates the analysis of the sidedness of ﬂecainide action.
Together, it is likely that external ﬂecainide diffuses
into cells through rapid equilibrium via its neutral com-
ponent, and, once inside, equilibrium is again estab-
lished with  99% of intracellular drug ionized. To fur-
ther test this hypothesis, using cell-attached recordings
of Na  channel activity, we applied ﬂecainide to the cell
outside of the patched area. Under these conditions,
external drug application should only block channels if
access to the drug-binding site occurs via a pathway that
allows the drug to enter the cytoplasm by passing
through the cell membrane. As shown in Fig. 9, exter-
nal application of ﬂecainide (10  M) indeed causes
UDB of channels recorded within the cell-attached
Figure 7. Test of sidedness of ﬂecain-
ide block using whole-cell recordings.
(A) UDB of WT Na  channels by exter-
nal and internal application of ﬂecain-
ide in whole-cell conﬁgurations. Cur-
rents were evoked by imposing condi-
tioning trains of 100–600 pulses ( 10
mV, 25 ms) from a holding potential of
 100 mV at a frequency of 10 Hz.
Pulses were applied until steady-state
UDB was achieved, as indicated by the
arrows. (B) Bar graphs summarize
steady-state UDB by external and inter-
nal application of ﬂecainide (10  M)
plotted as the fraction of current
blocked in response to pulse trains. n  
4–6 cells per condition.
Figure 8. Internally applied QX-FL
blocks whole-cell Na  channel activity.
(A) UDB of WT Na  channels by exter-
nal and internal application of QX-FL
in whole-cell conﬁgurations. Currents
were evoked by imposing conditioning
trains of 100–600 pulses ( 10 mV, 25
ms) from a holding potential of  100
mV at a frequency of 10 Hz. Pulses were
applied until steady-state UDB was
achieved. (B) Bar graphs summarize
steady-state UDB by external and inter-
nal application of QX-FL (10  M) plot-
ted as the fraction of current blocked in
response to pulse trains. n   4–6 cells
per condition. (C) Bar graphs summa-
rize steady-state UDB by external and
internal application of QX-314 plotted
as the fraction of current blocked in re-
sponse to pulse trains. n   4–6 cells per
condition.T
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patch, and this block is completely, and rapidly, revers-
ible upon washout. In contrast, channels within the
patch are insensitive to external QX-FL (10  M), as ex-
pected for a drug lacking a neutral component.
Common Molecular Determinants of Lidocaine, NU-FL, and 
QX-FL Channel Block
Local anesthetics have been shown to interact with spe-
ciﬁc sites in domains I, III, and IV of voltage-gated Na
channels (Ragsdale et al., 1994, 1996; Wang et al., 1998;
Catterall, 2002; Yarov-Yarovoy et al., 2002). Because of
the differences in physical chemical properties of
lidocaine and ﬂecainide, the effects of site-speciﬁc mu-
tations on drug block of channels has required differ-
ent voltage protocols (Ragsdale et al., 1994, 1996), sug-
gesting that the different drug structures may deﬁne
unique interaction sites (Li et al., 1999). In particular,
the mutations F1764A and Y1771A in transmembrane
segment IVS6 of the brain type IIA Na  channel   sub-
unit dramatically reduced block of inactivated channels
by lidocaine (Ragsdale et al., 1996). We prepared the
homologous mutants F1760A and Y1767A in the hu-
man cardiac sodium channel   subunit and tested the
effects of these mutations on block by NU-FL and QX-
FL. As was the case for the brain channel, we ﬁnd that
these mutations have little effect on drug-free channel
activity although the F1760A mutation causes a positive
shift of channel availability (Fig. 10 A). We ﬁrst deter-
mined if the homologous mutations in the human car-
diac channel would disrupt the lidocaine-induced hy-
perpolarization of channel availability. Our ﬁndings,
consistent with those reported in the literature for mu-
tations of the rat cardiac Na  channel, indicate that
both mutations reduce this shift, but the effect is most
pronounced for the F1760A mutation (Fig. 10, C
and D).
The F1760A and Y1767A mutations in human heart
Na  channels have a very similar effect on the interac-
tions of NU-FL with channel availability. As is the case
for lidocaine, the F1760A mutation virtually ablates the
NU-FL–induced hyperpolarization of the availability
curve, whereas the Y1767A mutation reduces, but does
not eliminate, this shift (Fig. 11, A and B). In light of
the fact that the mutations disrupt both the shift of the
inactivation curve induced by the neutral analogue we
reasoned that the afﬁnity of the neutral analogue for
the inactivated state of the mutant channels should
likewise be attenuated. Consequently, and similar to
the previously reported effects on lidocaine (Ragsdale
et al., 1996), both mutations alter the afﬁnity of NU-FL
for block of inactivated channels (Fig. 11 C).
Our ﬁndings support the notion of a common bind-
ing site in the channel pore for both NU-FL and
lidocaine. In addition, these data clearly suggest a rela-
tionship that the charge carried by ﬂecainide most
likely acts to restrict its access to this common site of ac-
tion. This suggestion is consistent with the data summa-
Figure 9. Cell-attached recordings reveal ﬂecainide access to LA-receptor through the cell membrane. (A) UDB of WT Na  channels by
external application of ﬂecainide and QX-FL in cell-attached conﬁgurations. Currents were evoked by imposing conditioning trains of
100–200 pulses ( 20 mV, 25 ms) from a holding potential of  120 mV at a frequency of 1 Hz. Pulses were applied until steady-state UDB
was achieved. (B) Bar graphs summarize steady-state UDB by external application of ﬂecainide and QX-FL plotted as the fraction of cur-
rent blocked in response to pulse trains. n   2–3 cells per condition.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
G
e
n
e
r
a
l
 
P
h
y
s
i
o
l
o
g
y
209 Liu et al.
rized in Fig. 12 A that indicate that these two IVS6 mu-
tations disrupt Na  channel UDB by NU-FL in the
same rank order as they disrupt UDB by ﬂecainide and
lidocaine despite the fact that, as shown above, NU-FL
UDB is dominated by charged drug interactions with
the channel. Furthermore, as shown in Fig. 12 A, we
ﬁnd that the F1760A mutation has pronounced effects
on UDB by QX-FL. The F1760A mutation causes an
eightfold reduction (37.3   1.7% for WT vs. 4.0  
0.9% for F1760A, n   3–5 cells) in UDB block by QX-
FL (applied internally), an effect similar to that on
UDB by externally applied ﬂecainide. Further, both
ﬂecainide and QX-FL have no effects on the recovery
rate of F1760A mutant channels (Fig. 12, B and C).
These data support the notion of a common binding
site in the pore for lidocaine, ﬂecainide, and both neu-
tral and quaternary ﬂecainide analogues.
QX-FL Unblocks Na  Channels without Channel Openings
Interestingly, channels recover from QX-FL block (very
slowly) at negative potentials where channel openings
are rare or nonexistent (Fig. 3), despite the require-
ment of channel openings for the development of QX-
FL block. Using single channel measurements, we
tested for, but did not ﬁnd evidence of, infrequent
channel openings at the  100mV holding potential,
and thus conclude that a pathway must exist via which
the ionized drug may exit from closed channels. Tetro-
dotoxin (TTX) is thought to block the extracellular
mouth of Na  channel (Hille, 1975; Terlau et al., 1991)
Figure 10. Effects of mutations of key residues of LA-receptor on Na  channel gating and lidocaine block. (A) Averaged inactivation
and activation curves for WT, F1760A, and Y1767A Na  channels. The voltage-dependence for the inactivation was measured as described
in Fig. 5. The voltage dependence of activation was measured by normalizing currents measured during pulses (25 ms) from  80 mV to
50 mV (5-mV increments) to driving force. Experimental data were ﬁtted with Boltzmann relationships (Fig. 5) to obtain the parameters
that follow. For inactivation: V1/2 (mV)    69.2   0.79 (WT);  60.6   0.51 (F1760A); and  67.5   0.63 (Y1767A). The slope factor, VK is
6.46   0.36 (WT); 5.41   0.18 (F1760A); 6.74   0.33 (Y1767A). For activation: V1/2 (mV) is  25.3   1.2 (WT);  23.3   1.4 (F1760A);
and  23.8   1.3 (Y1767A). The slope factor, VK, is 7.1   0.9 (WT); 7.2   0.7 (F1760A); and 7.4   0.6 (Y1767A). n   4–6 cells per condi-
tion. (B–D) Mutations hhF1760A and hhY1767A reduce block of inactivated Na  channel for lidocaine. Steady-state inactivation was mea-
sured as described in Fig. 5. Experimental data were ﬁtted with Boltzmann relationships (Fig. 5) and the drug-induced shift in channel
availability ( V1/2) was determined from V1/2,drug   V 1/2,control using V1/2 values obtained from ﬁts of the data. For WT, F1760A, and
Y1767A,  V1/2 (mV) is  17.65   1.17,  1.1   0.30, and  9.67   0.65 with 300  M lidocaine, respectively (n   4–6 cells per condition).T
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210 Na  Channel Block by Neutral Flecainide
and has been used to examine whether permanently
charged local anesthetics can exit through the extracel-
lular end of the pore (Qu et al., 1995). To test whether
QX-FL exits from closed channels through the extra-
cellular mouth of the pore, the rates of recovery from
QX-FL UDB were measured in the present of 30  M
TTX, which blocks  95% of resting cardiac Na chan-
nels in a rapidly reversible manner. If QX-FL exits
through the outer mouth of the pore, TTX should re-
duce the rate of recovery of QX-FL block. Consistent
with this prediction, as illustrated in Fig. 13, exposure
of 30  M TTX for 30 s during a total 60-s recovery pe-
riod signiﬁcantly reduces the rate of recovery after
UDB (P   0.01, n   4–6 cells). To determine whether
or not this TTX-induced reduction in recovery from
block might be due, in part, to inhibition of Na  entry
through open channels during the recovery period, we
tested the effects of Na -removal on recovery from
block. As shown in Fig. 13, we found no difference in
the effects of TTX on recovery whether or not Na  was
present in the external solution. Thus, the extracellular
mouth of the pore participates in the exit route for QX-
FL apparently whether or not channels are in the open
conformation.
DISCUSSION
The results of this study show for the ﬁrst time that the
degree of ionization of ﬂecainide molecules at physio-
logical pH deﬁnes the mechanism of action of the drug
and confers upon the drug molecules the prerequisite,
during repetitive activity, that channels must ﬁrst open
before channel block can accumulate (UDB). Reduc-
tion of the pKa of the drug molecule from 9.3 to 6.4
yielded a ﬂecainide analogue (NU-FL) for which 90%
of the drug molecules are neutral at pH 7.4, compared
Figure 11. Effects of mutations of LA-receptor on NU-FL block. (A and B) Mutations F1760A and Y1767A reduce block of inactivated
Na  channel for NU-FL. Steady-state inactivation was measured as described in Fig. 5. Experimental data were ﬁtted with Boltzmann rela-
tionships (Fig. 5). The drug-induced shift in channel availability ( V1/2) was determined from V1/2,drug   V1/2,control using V1/2 values ob-
tained from ﬁts of the data. For WT, F1760A, and Y1767A,  V1/2 (mV) is  9.17   1.04,  1.57   0.15, and  4.65   0.57 with 100  M
NU-FL, respectively. n   3–5 cells per condition. (C) Mutation F1760A and Y1767A reduce the afﬁnity of inactivated channel for NU-FL.
The block of inactivated Na  channels was measured as described in Fig. 6. Experimental data were ﬁtted with the Hill equation; these
gave estimates of EC50 for NU-FL binding to the inactivated channels. For WT, F1760A, and Y1767A, EC50 for NU-FL are 5.32   0.51  M,
134.9   9.96  M, and 53.7   5.55  M, respectively (n   3–5 cells per condition).T
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with  1% neutral ﬂecainide molecules at the same pH.
With this change in drug structure, the molecular phar-
macology of the custom synthesized drug was remark-
ably similar to the well-characterized Na  channel
blocker lidocaine.
The Charged Form of Flecainide Is the Active Form for UDB
UDB by LA drugs is the hallmark of their antiarrhyth-
mic activity, it enables these drugs to be more effective
when the frequency of action potentials is high, such as
in ventricular tachycardia (Rosen et al., 1975; Rosen
and Wit, 1983; Wit and Rosen, 1983). During UDB,
channel block accumulates because of incomplete re-
covery of drug-bound channels during diastole (inter-
stimulus intervals). Slowed recovery of drug-bound
channels can be explained by a combination of the
modulated-receptor hypothesis and the guarded-recep-
tor model (Hille, 1977a; Hondeghem and Katzung,
1977; Starmer et al., 1984). The modulated receptor
hypothesis proposes that higher afﬁnity for LA drugs
during activated and inactivated gating states slows un-
binding of drug and, consequently, recovery of the
drug-bound channels (Hille, 1977a; Hondeghem and
Katzung, 1977). The guarded-receptor model empha-
sized that a state-dependent availability of the drug ac-
cess path to and from the binding site inﬂuence appar-
ent binding and unbinding kinetics (Starmer et al.,
1984). Both of these hypotheses suggest that there is
Figure 12. UDB of WT and mutant Na  channels by ﬂecainide, NU-FL, QX-FL, and lidocaine. (A) Currents were evoked by imposing
conditioning trains of 100–600 pulses ( 10 mV, 25 ms) from a holding potential of  100 mV at a frequency of 10 Hz. Pulses were applied
until steady-state UDB was achieved. Bar graphs summarize steady-state UDB by ﬂecainide (10  M), NU-FL (100  M), QX-FL (100  M, in-
ternal), and lidocaine (300  M) plotted as the fraction of current blocked in response to pulse trains. (B) Recovery of F1760A channels
from drug block, measured as described in Fig. 3 legend, for ﬂecainide (10  M, left) and QX-FL (100  M, internal, right).T
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212 Na  Channel Block by Neutral Flecainide
common binding site for tertiary amine LAs. In this
study, our data clearly showed that UDB develops pre-
dominantly by the charged forms of both ﬂecainide
and NU-FL. What are the explanations for the weak-
ness of UDB of Na  channels by the neutral form of
ﬂecainide? First, the neutral form may occupy a bind-
ing site that is distinct from the binding site for
charged form of ﬂecainide. However, our data didn’t
support the existence of a separate neutral LA binding
site apart from the charged form binding site. Second,
the recovery time course of the neutral form of ﬂecain-
ide is fast (too fast to accumulate the UDB) and is com-
parable to recovery time course of fast Na inactivation
(Hille, 1977a; Yeh and Tanguy, 1985). As a result, upon
dissociation neutral ﬂecainide simply diffuses away
through a hydrophobic pathway. This possibility is
likely as the recovery from NU-FL block in solutions
buffered to pH 5.5, when the ratio of neutral to
charged forms of NU-FL are reversed, is greatly slowed,
consistent with the higher UDB level at the same condi-
tion. Thus, our results clearly indicate that the charged
form of ﬂecainide is the active form that underlies
UDB, which is the reported mechanism of action of
lidocaine (Strichartz, 1973; Wang et al., 1995).
Flecainide Access to an Intracellular Pathway: A Role of 
Neutral Drug
If ﬂecainide is 99% ionized at physiological pH, how
does external ﬂecainide application result in internal
access of the charged form of the drug to the inner
mouth of the channel pore? The results presented in
Fig. 9 provide a clue to this question. Because ﬂecain-
ide, applied outside the area under the patch elec-
trode, blocked channels recorded in cell-attached
patches, the drug had to diffuse across the cell mem-
brane in order to reach the patched channels. This
must occur via the neutral ﬂecainide component,
which crosses the membrane and then equilibrates in
the intracellular solution again in neutral (1%) and
charged (99%) forms. A similar sequence must also oc-
cur across the membrane of the patch, but in this case
both the difference in membrane area (patch to whole
cell) and the volume of the absorbing solution (pipette
volume compared with volume of the cell), would limit
the drug concentration of the pipette solution. That
this is likely the case is evidenced by the rapid revers-
ibility of drug block, which occurs when the extra-patch
ﬂecainide is removed in these experiments (Fig. 9).
An indirect role of the neutral ﬂecainide component
in the development of use-dependent block of exter-
nally applied drug is also supported by the experiments
of Figs. 8 and 9, which show that QX-FL is not effective
when applied externally outside of the patched area
(Fig. 9), but when applied intracellularly, as effectively
as extracellularly applied ﬂecainide (Fig. 7). The sim-
plest interpretation of these results is that neutral
ﬂecainide diffuses across the lipid bilayer of the cell
membrane, equilibrates in the intracellular compart-
ment where, as in the extracellular solution, 99% of the
ﬂecainide molecules in equilibrium are ionized. Use-
dependent block that occurs, most likely develops as a
consequence of the intracellular charged ﬂecainide
molecules.
Receptor Access Distinguishes Lidocaine and Flecainide 
Activity and Underlies Distinct Therapeutic Proﬁles
As has previously been the case for the quaternary
lidocaine analogue QX-314, QX-FL provides unique in-
sight into the access of a charged ﬂecainide analogue
to a common local anesthetic receptor-binding site on
the Na  channel. Studies using alanine-scanning mu-
tagenesis have provided a detailed picture of compo-
Figure 13. Outer pore block by TTX impedes recovery from
QX-FL block. WT channels were blocked by QX-FL (100  M, in-
ternal application). UDB was induced by trains of 100 pulses ( 10
mV, 25 ms, 25 Hz) from a  100 mV holding potential. Test pulses
were then imposed after 60-s intervals at  100 mV to assay recov-
ery from block. The protocol was performed in the absence and
then in the presence of TTX (30  M) during the ﬁrst 30 s of the
60-s recovery period (see schematic). The bars graphs summarize
the fraction of recovery from QX-FL block in the absence and
presence of TTX in external solutions containing 130 mM NaCl.
The hatched bars summarize similar experiments recorded in Na-
free conditions (Na  was replaced by n-methyl-glucamine). n  
4–6 cells per condition. ***, P   0.05 compared with TTX-free
conditions in both Na  -containing and Na -free solutions.T
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nents of a local anesthetic receptor site for which resi-
dues on the S6 segments of domains I, III, and IV con-
tribute (Ragsdale et al., 1994, 1996; Wang et al., 1998;
Catterall, 2002; Yarov-Yarovoy et al., 2002). Alanine-
scanning mutagenesis indicates that residues in at least
domains III and IV that contribute to the receptor site
are likely to face the inner pore region of the channel
(Catterall, 2002; Yarov-Yarovoy et al., 2002), and that
rotational movement of S6 segments during activation
and inactivation are likely to alter access to this site
from the intracellular region of the channel (Perozo et
al., 1999; del Camino et al., 2000).
We have shown previously that ﬂecainide UDB re-
quires channels to open but that block is very sensitive
to alterations in channel inactivation (Liu et al., 2002).
We now ﬁnd that ionized ﬂecainide, which accounts for
the distinct UDB of the drug, gains access to its recep-
tor via an intracellular pathway after channels open.
Mutation of the key Phe residue in the local anesthetic
receptor disrupts channel block by lidocaine, ﬂecain-
ide, neutral ﬂecainide (NU-FL), and ionized ﬂecainide
(QX-FL). Together, these results are very consistent
with a common receptor shared by lidocaine and
ﬂecainide, access to which is restricted by differences in
ionization of the two compounds as predicted by the
modulated receptor hypothesis. Our data strongly sug-
gest that transitions into the open state change intracel-
lular access of ionized ﬂecainide to the receptor site de-
ﬁned by residues on the S6 segments lining the inner
pore, and like lidocaine, block by ﬂecainide is stabi-
lized by further transitions into the inactivated state
(Liu et al., 2002).
Interestingly, despite the apparent restricted access
to inner pore receptor from closed, rested states, we
ﬁnd that channels blocked by charged ﬂecainide (QX-
FL) recover from channel block, albeit very slowly, at
negative potentials even in the absence of channel
openings (Fig. 3). Thus there must be a pathway avail-
able for drug exit at rest. The facts that outer pore
block by TTX slows the recovery of channels from QX-
Fl block, even at voltages in which channels do not
open, and that removal of extracellular Na  has no ef-
fect on the recovery from channel block provide strong
evidence that the drug can dissociate from channels at
rest and diffuse slowly through the outer pore in a
pathway to permit very slow recovery from block. Thus,
in many ways the fundamental mechanisms of action of
QX-FL and the charged lidocaine analogue QX-314 are
very similar, indicating that it is the differences in distri-
bution of charged and neutral forms of ﬂecainide and
lidocaine and not differences in chemical structures
that accounts for the distinct voltage-dependent pro-
ﬁles of the two drugs. As predicted by the modulated
receptor hypothesis (Hille, 1977a; Hondeghem and
Katzung, 1977), it thus appears that hydrophobic and
hydrophilic access pathways to a common LA receptor
in fact can explain the differences in activities of these
two important drugs and must be addressed in consid-
ering novel analogues that may be useful in the treat-
ment of cardiac electrical defects that are caused by in-
herited mutations of SCN5A, the gene coding for the  
subunit of the cardiac Na  channel.
That ﬂecainde has proven to be particularly useful in
the treatment of variant 3 of the long QT syndrome
and as a diagnostic tool in identifying potential Bru-
gada syndrome patients has raised the interest in un-
derstanding the mechanistic basis of mutation-altered
interactions of the drug with cardiac Na  channels.
Since the neutral components of lidocaine and ﬂecain-
ide, as evidenced by the data presented in this study, ap-
pear to interact with a common receptor and cause
nearly identical changes in channel activity, it is most
likely mutation-induced alteration in the access of the
charged form of ﬂecainide to a common LA receptor
site that accounts for the unique therapeutic efﬁcacy
of this drug. Analysis of the effects of ﬂecainide on
disease-associated mutations that independently alter
channel mean open time and/or the voltage depen-
dence of channel availability has provided evidence in
support of this view (Liu et al., 2002).
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